Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus

Diabetes and Metabolism

Volumn 42, Issue 5, 2016, Pages 358-363

  Hu, Y ^a   Liu, J ^a   Zhang, H ^a   Xu, Y ^a   Hong, T ^b   Wang, G ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

Exenatide; FGF21; Insulin resistance; Type 2 diabetes

Indexed keywords

C PEPTIDE; EXENDIN 4; FIBROBLAST GROWTH FACTOR 21; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; FIBROBLAST GROWTH FACTOR; PEPTIDE; VENOM;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TREATMENT DURATION; BLOOD; CASE CONTROL STUDY; DIABETES MELLITUS, TYPE 2; METABOLISM; MIDDLE AGED;

ADULT; AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FIBROBLAST GROWTH FACTORS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MIDDLE AGED; PEPTIDES; VENOMS;

EID: 84975147708     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2016.04.005     Document Type: Article

References (31)

1. [1] Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142 (2012), 1592–1609.
2. [2] Nishimura, T., Nakatake, Y., Konishi, M., Itoh, N., Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 1492 (2000), 203–206.
3. [3] Liu, J., Xu, Y., Hu, Y., Wang, G., The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy. Metabolism 64 (2015), 380–390.
4. [4] Chavez, A.O., Molina-Carrion, M., Abdul-Ghani, M.A., Folli, F., Defronzo, R.A., Tripathy, D., Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 32 (2009), 1542–1546.
5. [5] Wente, W., Efanov, A.M., Bfenner, M., Kharitonenkov, A., Köster, A., Sandusky, G.E., et al. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 55 (2006), 2470–2478.
6. [6] Kharitonenkov, A., Shiyanova, T.L., Koester, A., Ford, A.M., Micanovic, R., Galbreath, E.J., et al. FGF-21 as a novel metabolic regulator. J Clin Invest 115 (2005), 1627–1635.
7. [7] Yang, M., Dong, J., Liu, H., Li, L., Yang, G., Effects of short-term continuous subcutaneous insulin infusion on fasting plasma fibroblast growth factor-21 levels in patients with newly diagnosed type 2 diabetes mellitus. PLoS ONE, 6, 2011, e26359.
8. [8] Mraz, M., Bartlova, M., Lacinova, Z., Michalsky, D., Kasalicky, M., Haluzikova, D., et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf) 71 (2009), 369–375.
9. [9] Cheng, X., Zhu, B., Jiang, F., Fan, H., Serum FGF-21 levels in type 2 diabetic patients. Endocr Res 36 (2011), 142–148.
10. [10] Li, K., Li, L., Yang, M., Zong, H., Liu, H., Yang, G., Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus. Eur J Endocrinol 161 (2009), 391–395.
11. [11] Zhang, M., Liu, Y., Xiong, Z.Y., Deng, Z.Y., Song, H.L., An, Z.M., Changes of plasma fibroblast growth factor-21 (FGF-21) in oral glucose tolerance test and effects of metformin on FGF-21 levels in type 2 diabetes mellitus. Endokrynol Pol 64 (2013), 220–224.
12. [12] Fisher, F.M., Chui, P.C., Antonellis, P.J., Bina, H.A., Kharitonenkov, A., Flier, J.S., et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 59 (2010), 2781–2789.
13. [13] Jinnouchi, H., Sugiyama, S., Yoshida, A., Hieshima, K., Kurinami, N., Suzuki, T., et al. Liraglutide, a glucagon-like peptide-1 analogy, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus. J Diabetes Res, 2015, e706416.
14. [14] Samson, S.L., Sathyanarayana, P., Jogi, M., Gonzalez, E.V., Gutierrez, A., Krishnamurthy, R., et al. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. Diabetologia 54 (2011), 3093–3100.
15. [15] Nonogaki, K., Hazama, M., Satoh, N., Liraglutide suppresses obesity and hyperglycemia associated with increases in hepatic fibroblast growth factor 21 production in KKAy mice. Biomed Res Int, 2014, e751930.
16. [16] Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1995), 412–419.
17. [17] Yang, M., Zhang, L., Wang, C., Liu, H., Boden, G., Yang, G., et al. Liraglutide increases FGF-21 activity and insulin sensitivity in high fat diet and adiponectin knockdown induced insulin resistance. PLoS ONE, 7, 2012, e48392.
18. [18] Dushay, J., Chui, P.C., Gopalakrishnan, G.S., Varela-Rey, M., Crawley, M., Fisher, F.M., et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 139 (2010), 456–463.
19. [19] Zhang, X., Yeung, D.C., Karpisek, M., Stejskal, D., Zhou, Z.G., Liu, F., et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57 (2008), 1246–1253.
20. [20] Hanssen, M.J., Broeders, E., Samms, R.J., Vosselman, M.J., van der Lans, A.A., Cheng, C.C., et al. Serum FGF21 levels are associated with brown adipose tissue activity in humans. Sci Rep, 5, 2015, 10275.
21. [21] Giralt, M., Gavaldà-Navarro, A., Villarroya, F., Fibroblast growth factor-21, energy balance and obesity. Mol Cell Endocrinol 418 (2015), 66–73.
22. [22] Díaz-Delfín, J., Hondares, E., Iglesias, R., Giralt, M., Caelles, C., Villarroya, F., et al. TNF-α represses β-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. Endocrinology 153 (2012), 4238–4245.
23. [23] Samson, S.L., Gonzalez, E.V., Yechoor, V., Bajaj, M., Oka, K., Chan, L., Gene therapy for diabetes: metabolic effects of helper-dependent adenoviral exendin 4 expression in a diet-induced obesity mouse model. Mol Ther 16 (2009), 1805–1812.
24. [24] Gastaldelli, A., Nauck, M.A., Balena, R., Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes. Metabolism 62 (2013), 1330–1339.
25. [25] Kenny, P.R., Brady, D.E., Torres, D.M., Ragozzino, L., Chalasani, N., Harrison, S.A., Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series. Am J Gastroenterol 105 (2010), 2707–2709.
26. [26] Singhal, G., Fisher, F.M., Chee, M.J., Tan, T.G., El Ouaamari, A., Adams, A.C., et al. Fibroblast growth factor 21 (FGF21) protects against high fat diet induced inflammation and islet hyperplasia in pancreas. PLOS ONE, 11, 2016, e0148252.
27. [27] Scheen, A.J., Esser, N., Paquot, N., Antidiabetic agents: potential anti-inflammatory activity beyond glucose control. Diabetes Metab 41 (2015), 183–194.
28. [28] Emoto, M., Nishizawa, Y., Maekawa, K., Hiura, Y., Kanda, H., Kawagishi, T., et al. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulphonylureas. Diabetes Care 22 (1999), 818–822.
29. [29] Matsuda, M., DeFronzo, R., Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22 (1999), 1462–1470.
30. [30] Mari, A., Pacini, G., Murphy, E., Ludvik, B., Nolan, J.J., A model-based method for assessing insulin sensitivity from the OGTT. Diabetes Care 24 (2001), 539–548.
31. [31] Brun, J.F., Raynaud, E., Mercier, J., Homeostasis model assessment and related simplified evaluations of insulin sensitivity from fasting insulin and glucose. Diabetes Care 23 (2000), 1037–1038.